Home › Trials › NCT05904028

Home OCT-guided treatment for neovascular AMD management

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Phase 3 Interventional Jaeb Center for Health Research · NCT05904028

This study tests if using home monitoring with a special eye scan can help people with neovascular age-related macular degeneration see better and make treatment easier compared to the usual method.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment600 (estimated)
Ages50 Years and up
SexAll
SponsorJaeb Center for Health Research Academic / other
Drugs / interventionsfaricimab
Locations64 sites (Glendale, California and 63 other locations)
Trial IDNCT05904028 on ClinicalTrials.gov

What this trial studies

This clinical trial compares two treatment approaches for managing neovascular age-related macular degeneration (nAMD): a home optical coherence tomography (OCT)-guided treatment strategy and a standard 'Treat and Extend' regimen. The study aims to determine if daily monitoring with home OCT can lead to better visual acuity outcomes and reduced treatment burden compared to traditional methods. Participants will receive intravitreal injections of faricimab while undergoing either treatment approach over a two-year period. The trial seeks to personalize treatment by utilizing home monitoring to optimize injection frequency and improve disease management.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 50 and older with untreated, active macular neovascularization secondary to age-related macular degeneration.

Not a fit: Patients who have previously received treatment for macular neovascularization may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to improved visual outcomes and reduced treatment burden for patients with neovascular AMD.

How similar studies have performed: Other studies have shown promise in using home monitoring technologies for chronic conditions, but this specific approach is novel in the context of nAMD management.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

* Age ≥ 50 years
* Have the capacity to consent on his/her own behalf
* Able to successfully and independently complete at least one self-scanning session on the Home OCT device located at the enrolling clinical site
* Willing to perform once daily Home OCT monitoring tests for 2 years without significant interruption (such as travel of more than 14 days)
* Best corrected E-ETDRS visual acuity ≥24 ETDRS letters (approximately 20/320 or better (Snellen))
* Previously untreated, active MNV lesion (i.e., any intraretinal or subretinal fluid within the center 3 mm diameter circle on OCT) secondary to age-related macular degeneration
* ≥ 1 intermediate drusen (≥ 63 microns) in either eye OR late AMD (MNV or macular atrophy) in the contralateral eye

Key Exclusion Criteria for Study Eye:

* Previous treatment for MNV (intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent, or any other AMD therapy)
* Prior treatment with intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent or with macular laser for any indication
* Treatment with intravitreal corticosteroids within the last 6 months
* A condition that, in the opinion of the investigator, would preclude participation in the study or ability to complete daily Home OCT scans for 2 years (e.g., unstable medical status that may preclude successful completion of follow-up, dementia, Alzheimer's disease, uncontrollable tremors)
* MNV due to other causes, such as ocular histoplasmosis, central serous choroidopathy, or pathologic myopia

Where this trial is running

Glendale, California and 63 other locations

+14 more sites — see ClinicalTrials.gov for the full list.

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Neovascular Age-related Macular Degenerationoptical coherence tomography
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.